COVID-19 Drug Discovery Using Intensive Approaches
Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines a...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2020-04, Vol.21 (8), p.2839 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 2839 |
| container_title | International journal of molecular sciences |
| container_volume | 21 |
| creator | Asai, Ayumu Konno, Masamitsu Ozaki, Miyuki Otsuka, Chihiro Vecchione, Andrea Arai, Takahiro Kitagawa, Toru Ofusa, Ken Yabumoto, Masami Hirotsu, Takaaki Taniguchi, Masateru Eguchi, Hidetoshi Doki, Yuichiro Ishii, Hideshi |
| description | Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable. |
| doi_str_mv | 10.3390/ijms21082839 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7215413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2394908354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-83e77c1e9f2cfe2802db6ced685c3acdd455584b0265cca2361996ed8de7a7783</originalsourceid><addsrcrecordid>eNpdkUtLw0AUhQdRbK3uXEvAjQuj88hkZjZCaX0UCt1Yt8N0ctOm5FFnkkL_vQmtpbq6B-7H4Z57ELol-IkxhZ-zdeEpwZJKps5Qn0SUhhjH4vxE99CV92uMKaNcXaIe64SIRR_R0exrMg6JCsauWQbjzNtqC24XzH1WLoNJWUPpsy0Ew83GVcauwF-ji9TkHm4Oc4Dmb6-fo49wOnufjIbT0EZC1qFkIIQloFJqU6AS02QRW0hiyS0zNkkizrmMFpjG3FpDWUyUiiGRCQgjhGQD9LL33TSLAhILZe1MrjcuK4zb6cpk-u-mzFZ6WW21oIRHhLUGDwcDV3034GtdtPEgz00JVeM1ZSpSWDIetej9P3RdNa5s43UUkxGncWf4uKesq7x3kB6PIVh3ZejTMlr87jTAEf79PvsBZvOELw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393845263</pqid></control><display><type>article</type><title>COVID-19 Drug Discovery Using Intensive Approaches</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Asai, Ayumu ; Konno, Masamitsu ; Ozaki, Miyuki ; Otsuka, Chihiro ; Vecchione, Andrea ; Arai, Takahiro ; Kitagawa, Toru ; Ofusa, Ken ; Yabumoto, Masami ; Hirotsu, Takaaki ; Taniguchi, Masateru ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Ishii, Hideshi</creator><creatorcontrib>Asai, Ayumu ; Konno, Masamitsu ; Ozaki, Miyuki ; Otsuka, Chihiro ; Vecchione, Andrea ; Arai, Takahiro ; Kitagawa, Toru ; Ofusa, Ken ; Yabumoto, Masami ; Hirotsu, Takaaki ; Taniguchi, Masateru ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Ishii, Hideshi</creatorcontrib><description>Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21082839</identifier><identifier>PMID: 32325767</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antiviral agents ; Antiviral Agents - chemistry ; Antiviral Agents - therapeutic use ; Betacoronavirus ; Chemical compounds ; China ; Clinical trials ; Coronaviridae ; Coronavirus Infections - drug therapy ; Coronaviruses ; COVID-19 ; COVID-19 Drug Treatment ; Drug development ; Drug Discovery ; Drugs ; Humans ; Infectious diseases ; Pandemics ; Pharmacology ; Pneumonia, Viral - drug therapy ; Review ; RNA viruses ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Signs and symptoms ; Vaccines ; Viral infections ; Viruses</subject><ispartof>International journal of molecular sciences, 2020-04, Vol.21 (8), p.2839</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-83e77c1e9f2cfe2802db6ced685c3acdd455584b0265cca2361996ed8de7a7783</citedby><cites>FETCH-LOGICAL-c478t-83e77c1e9f2cfe2802db6ced685c3acdd455584b0265cca2361996ed8de7a7783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215413/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215413/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32325767$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Asai, Ayumu</creatorcontrib><creatorcontrib>Konno, Masamitsu</creatorcontrib><creatorcontrib>Ozaki, Miyuki</creatorcontrib><creatorcontrib>Otsuka, Chihiro</creatorcontrib><creatorcontrib>Vecchione, Andrea</creatorcontrib><creatorcontrib>Arai, Takahiro</creatorcontrib><creatorcontrib>Kitagawa, Toru</creatorcontrib><creatorcontrib>Ofusa, Ken</creatorcontrib><creatorcontrib>Yabumoto, Masami</creatorcontrib><creatorcontrib>Hirotsu, Takaaki</creatorcontrib><creatorcontrib>Taniguchi, Masateru</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Ishii, Hideshi</creatorcontrib><title>COVID-19 Drug Discovery Using Intensive Approaches</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - chemistry</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Betacoronavirus</subject><subject>Chemical compounds</subject><subject>China</subject><subject>Clinical trials</subject><subject>Coronaviridae</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Drug development</subject><subject>Drug Discovery</subject><subject>Drugs</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Pandemics</subject><subject>Pharmacology</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Review</subject><subject>RNA viruses</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signs and symptoms</subject><subject>Vaccines</subject><subject>Viral infections</subject><subject>Viruses</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtLw0AUhQdRbK3uXEvAjQuj88hkZjZCaX0UCt1Yt8N0ctOm5FFnkkL_vQmtpbq6B-7H4Z57ELol-IkxhZ-zdeEpwZJKps5Qn0SUhhjH4vxE99CV92uMKaNcXaIe64SIRR_R0exrMg6JCsauWQbjzNtqC24XzH1WLoNJWUPpsy0Ew83GVcauwF-ji9TkHm4Oc4Dmb6-fo49wOnufjIbT0EZC1qFkIIQloFJqU6AS02QRW0hiyS0zNkkizrmMFpjG3FpDWUyUiiGRCQgjhGQD9LL33TSLAhILZe1MrjcuK4zb6cpk-u-mzFZ6WW21oIRHhLUGDwcDV3034GtdtPEgz00JVeM1ZSpSWDIetej9P3RdNa5s43UUkxGncWf4uKesq7x3kB6PIVh3ZejTMlr87jTAEf79PvsBZvOELw</recordid><startdate>20200418</startdate><enddate>20200418</enddate><creator>Asai, Ayumu</creator><creator>Konno, Masamitsu</creator><creator>Ozaki, Miyuki</creator><creator>Otsuka, Chihiro</creator><creator>Vecchione, Andrea</creator><creator>Arai, Takahiro</creator><creator>Kitagawa, Toru</creator><creator>Ofusa, Ken</creator><creator>Yabumoto, Masami</creator><creator>Hirotsu, Takaaki</creator><creator>Taniguchi, Masateru</creator><creator>Eguchi, Hidetoshi</creator><creator>Doki, Yuichiro</creator><creator>Ishii, Hideshi</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200418</creationdate><title>COVID-19 Drug Discovery Using Intensive Approaches</title><author>Asai, Ayumu ; Konno, Masamitsu ; Ozaki, Miyuki ; Otsuka, Chihiro ; Vecchione, Andrea ; Arai, Takahiro ; Kitagawa, Toru ; Ofusa, Ken ; Yabumoto, Masami ; Hirotsu, Takaaki ; Taniguchi, Masateru ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Ishii, Hideshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-83e77c1e9f2cfe2802db6ced685c3acdd455584b0265cca2361996ed8de7a7783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - chemistry</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Betacoronavirus</topic><topic>Chemical compounds</topic><topic>China</topic><topic>Clinical trials</topic><topic>Coronaviridae</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Drug development</topic><topic>Drug Discovery</topic><topic>Drugs</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Pandemics</topic><topic>Pharmacology</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Review</topic><topic>RNA viruses</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signs and symptoms</topic><topic>Vaccines</topic><topic>Viral infections</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Asai, Ayumu</creatorcontrib><creatorcontrib>Konno, Masamitsu</creatorcontrib><creatorcontrib>Ozaki, Miyuki</creatorcontrib><creatorcontrib>Otsuka, Chihiro</creatorcontrib><creatorcontrib>Vecchione, Andrea</creatorcontrib><creatorcontrib>Arai, Takahiro</creatorcontrib><creatorcontrib>Kitagawa, Toru</creatorcontrib><creatorcontrib>Ofusa, Ken</creatorcontrib><creatorcontrib>Yabumoto, Masami</creatorcontrib><creatorcontrib>Hirotsu, Takaaki</creatorcontrib><creatorcontrib>Taniguchi, Masateru</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Ishii, Hideshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Asai, Ayumu</au><au>Konno, Masamitsu</au><au>Ozaki, Miyuki</au><au>Otsuka, Chihiro</au><au>Vecchione, Andrea</au><au>Arai, Takahiro</au><au>Kitagawa, Toru</au><au>Ofusa, Ken</au><au>Yabumoto, Masami</au><au>Hirotsu, Takaaki</au><au>Taniguchi, Masateru</au><au>Eguchi, Hidetoshi</au><au>Doki, Yuichiro</au><au>Ishii, Hideshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 Drug Discovery Using Intensive Approaches</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2020-04-18</date><risdate>2020</risdate><volume>21</volume><issue>8</issue><spage>2839</spage><pages>2839-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32325767</pmid><doi>10.3390/ijms21082839</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2020-04, Vol.21 (8), p.2839 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7215413 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antiviral agents Antiviral Agents - chemistry Antiviral Agents - therapeutic use Betacoronavirus Chemical compounds China Clinical trials Coronaviridae Coronavirus Infections - drug therapy Coronaviruses COVID-19 COVID-19 Drug Treatment Drug development Drug Discovery Drugs Humans Infectious diseases Pandemics Pharmacology Pneumonia, Viral - drug therapy Review RNA viruses SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Vaccines Viral infections Viruses |
| title | COVID-19 Drug Discovery Using Intensive Approaches |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A46%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20Drug%20Discovery%20Using%20Intensive%20Approaches&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Asai,%20Ayumu&rft.date=2020-04-18&rft.volume=21&rft.issue=8&rft.spage=2839&rft.pages=2839-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21082839&rft_dat=%3Cproquest_pubme%3E2394908354%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2393845263&rft_id=info:pmid/32325767&rfr_iscdi=true |